First European Patent Grant

RNS Number : 6173S

Evgen Pharma PLC

04 October 2017

 

For immediate release	4 October 2017

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

First European Patent Grant

Grant of European patent for the manufacture and scale-up of SFX-01 

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the grant of the first European patent for SFX-01, the Company's lead product.

SFX-01 is a synthetic version of the naturally occurring compound sulforaphane, which has been stabilised in an alpha-cyclodextrin lattice. Evgen Pharma is currently conducting two Phase II trials of SFX-01, one in advanced breast cancer and one in a type of stroke called subarachnoid haemorrhage.

The patent granted today, which covers the manufacturing and scale-up of SFX-01, marks the first patent to be granted for SFX-01 in Europe, where a composition of matter patent is also pending. Today's patent grant marks the Company's eighth patent to be granted this year, reflecting the growth in the Company's patent estate.

The European patent, numbered EP2854861 and entitled Method of Synthesising Sulforaphane, can be viewed at this link: https://register.epo.org/application?number=EP13726846&tab=doclist. The patent runs until May 2033.

This core manufacturing patent has already been granted in the United States, Australia and Japan and is pending in other countries worldwide.

Evgen Pharma holds exclusive worldwide rights to all products, including SFX-01, and processes associated with the Sulforadex® technology platform under the terms of a licence agreement with the technology's inventor, US-based PharmAgra Labs Inc. 

Dr Stephen Franklin, CEO of Evgen Pharma, commented: "In March this year we stated that we would issue separate announcements only for significant patent grants in key territories and that we would give an update on all other grants in our full and half year results. We are therefore delighted to announce the grant of this core European manufacturing patent, which further strengthens our intellectual property position. This patent is particularly significant as it marks our first in Europe, further underpinning the Company's commercial potential worldwide."

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) John Howes, Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

 

END

 

 

REAFSIFADFWSEIS